Tulane Cancer Center Members: P

Tulane Cancer Center Members: P
Faculty Membership Application and Membership Definitions

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Pandey, Pandrea, Pearman, Pochampally, Price, Prockop

Kailash N. Pandey, Ph.D.
Professor of Physiology
TCC Contributing Member
kpandey@tulane.edu
(504) 988-1628, (504) 988-2675 fax
Box SL-39, 1430 Tulane Ave., New Orleans, LA 70122
Homepage on the Physiology website:
http://www.som.tulane.edu/departments/physiology/Faculty/FacultyPages/Pandey.html

Biographical Narrative:
Dr. Pandey received his Ph.D. in Cell Biology from the University of Kentucky in 1979. He carried out postdoctoral studies in the Department of Biochemistry at Vanderbilt University and in 1986 was appointed as a faculty member. In 1990 he joined the faculty of the Medical College of Georgia as an Associate Professor in the Department of Biochemistry and Molecular Biology. Dr. Pandey joined Tulane in 1997. He has served on the Editorial Board of Endocrinology and reviewed manuscripts for a number of other journals. He has served on AHA, NIH and NSF grant review committees. The long-term objectives of his research projects are to delineate the molecular and cellular action of atrial natriuretic peptide (ANP) hormone, which controls natriuresis, diuresis, cell proliferation, and steroidogenesis. The regulatory action of ANP is mediated by interacting with the guanylyl cyclase/natriuretic peptide receptor-A (NPRA) that synthesizes the intracellular second messenger cyclic-GMP. Interaction of ANP with the NPRA plays a central role in the pathophysiology of hypertension and cardiovascular disorders. The current studies in his laboratory are aimed at examining the structure-function relationship of different domains of NPRA cDNA by deletion and site-directed mutagenesis of the structural components that may be involved in ligand-binding, activation of protein kinase-like domain, cGMP production, and receptor down-regulation and desensitization. These studies involve the analysis of the molecular determinants in receptor sequence mediating the overall functional ability of NPRA, critical for the hormone-dependent signaling process. Dr. Pandey has expanded his recent studies to examine the transcriptional regulation and function of the murine NPRA gene promotor using model cell lines and the NPRA gene-targeted mutant mice generated by homologous recombination that either disrupted (knockout) or duplicated the NPRA gene. The impact of NPRA gene dosage and null mutation should help to determine the function of the receptor in vivo and in cultured cells in vitro. These ongoing studies should provide the means to directly test the efficacy of NPRA regulatory elements and the impact of NPRA gene dosage and null mutation in ANP/cGMP-mediated biological responses.

Recent Publications:

Pandey KN, Nguyen HT, Sharma GD, Shi S-J, Kreigel AM. "Ligand-regulated internalization, trafficking, and down-regulation of guanylyl cyclase/atrial natriuretic peptide receptor-A in human embryonic kidney 293 cells." J Biol Chem 277:4618-4627 (2002)
Garg R, Oliver PM, Maeda N, Pandey KN. "Genomic structure, organization, and promoter region analysis of murine guanylyl cyclase/atrial natriuretic peptide receptor-A gene." Gene 291:123-133 (2002)
Pandey KN, Nguyen HT, Garg R, Khurana ML, Fink J. "Internalization and trafficking of guanylyl cyclase/natriuretic peptide receptor-A is regulated by an acidic tyrosine-based cytoplasmic motif GDAY." Biochem J 388: 103-113 (2005)
Vellaichamy E, Khurana ML, Fink J, Pandey KN. "Involvement of NF-(Kappa) B matrix metalloproteinase pathway in cardiac fibrosis of mice lacking guanylyl cyclase/natriuretic peptide receptor-A." J Biol Chem 280: 19230-19242 (2005)

Ivona V. Pandrea, M.D., Ph.D.
Clinical Assistant Professor , Division of Comparative Pathology
Veterinary Pathologist
TCC Contributing Member
Tumor Immunology Program
ipandrea@tulane.edu
(985) 871-6408, (985) 871-6510 fax
18703 Three Rivers Rd., Covington, LA 70433
Medical campus mailbox SL-20

Research Interests:

The study of pathogenic determinants of FeLV in relation with lymphoma induction
Cell growth and differentiation in colorectal carcinomas
Treatment of bladder carcinomas by apoptosis inducers
Study of lymphomas in SIV-infected monkeys
Parthogenesis of SIV in natural hosts: African Green monkeys, mandrills, and sooty mangabeys.
The mechanism of CD4 T-cell destruction in pathogenic SIVmac infection in rhesus macaques.

Recent Publications:

Barbat A, Pandrea IV, Cambier D, Zeibaum A, Lesuffleur T. Resistance of the human colon carcinoma cell line HCT-8 to methotrexate results in selection of cells with features of enterocytic differentiation. Int J Cancer 75:731-717 (1998)
Lesuffleur T, Violette S, Vasile-Pandrea I, Dussaulx E, Barbat A, Muleris M, Zweibaum A. Resistance to high concentrations of methotrexate and 5-fluorouracil of differentiated HT-29 colon-cancer cells is restricted to cells of enterocytic phenotype. Int J Cancer 76:383-392 (1998)
Pandrea IV, Carriere V, Barbat A, Cambier D, Dussaulx E, Lesuffleur T, Rousset M, Zweibaum A. Postmitiotic differentiation of colon carcinoma Caco-2 cells does not prevent re-entry in the cell cycle and tumorigenicity. Exp Mol Pathol 69:37-45 (2000)
Bras-Concalves RA, Pocard M, Formento JL, Poirson-Bichat F, De Pinieux G, Pandrea IV, Arvelo F, Ronco G, Villa P, Coquelle A, Milano G, Lesuffleur T, Dutrillaux B, Poupon MF. Synergistic efficacy of 3n-butyrate and 5-fluorouracil in human colorectal cancer xenografts via modulation of DNA synthesis. Gastroenterology 120:874-888 (2001)
Ling B, Apetrei C, Pandrea IV, Veazey RS, Lackner AA, Gormus B, Marx PA. Classic AIDS in a sooty mangabey after 18 year natural infection. J Virol 78:8902-8909 (2004)
Chandhasin C, Coan PN, Pandrea IV, Grant CK, Lobelle-Rich PA, Puetter A, Levy LS. The unique LTR and SU gene of FeLV-945 as determinants of disease outcome. J Virol (in press) (2005)

Tim Pearman, Ph.D.
Director of the Patricia Trost-Friedler Counseling Center
Clinical Associate Professor of Psychiatry & Neurology
Schwartz Rounds coordinator
TCC Associate Member
tpearman@tulane.edu
(504) 988-6313, (504) 988-6348 fax
1415 Tulane Ave., Box HC-62
New Orleans, LA 70112-2699

Biographical Narrative:
Dr. Pearman received his bachelor's degree in Psychology from the Pennsylvania State University in 1991. He completed his training in Clinical & Health Psychology at the University of Florida, receiving his M.S. in 1994 and his Ph.D. in 1997. Dr. Pearman completed his clinical internship at the Tulane University Medical Center in 1997. Dr. Pearman was the Director of Psychiatric Services at Vencor Hospital in New Orleans and Chief Psychologist at East Lake Hospital before returning to Tulane as the Director of the Patricia Trost-Friedler Cancer Counseling Center at the Tulane Cancer Center. Dr. Pearman is currently a Clinical Assistant Professor in the Department of Psychiatry & Neurology at the Tulane University School of Medicine. Dr. Pearman's research interests focus on psychological predictors of survival and quality of life following bone marrow transplantation. Dr. Pearman's doctoral research showed a possible link between pre-transplant depression and anxiety and post-transplant survival time and quality of life. In addition, it appears that social support may be an important contributor in determining quality of life post-bone marrow transplant. Dr. Pearman is currently beginning multidisciplinary research examining quality of life in patients receiving treatment for metastatic brain tumors. Recent advances in radiation oncology have led to interventions such as stereotactic radiosurgery and stereotactic radiotherapy which are less damaging to healthy brain tissue, while remaining clinically effective in treatment of brain tumors. Dr. Pearman, in collaboration with Dr. Lucien Nedzi, Radiation Oncologist, will compare the quality of life of patients receiving these new treatments, as well as patients receiving conventional surgical treatment.

Recent Publications:

Rodrigue JR, Pearman TP, Moreb J. (1999) Morbidity and mortality following bone marrow transplantation: Predictive utility of pre-BMT affective functioning, compliance and social support stability. Int J Behav Med 6(3): 241-254.

Radhika Pochampally, Ph.D.
Assistant Professor of Pharmacology and Center for Gene Therapy
TCC Contributing Member
rpocham@tulane.edu
(504) 988-7715, (504) 988-7710 fax
1430 Tulane Ave., SL-99, New Orleans, LA 70112

Biographical Narrative:
Dr. Pochampally received her Ph.D. under the mentorship of Dr. Jiandong Chen from LSU Health Sciences Center, New Orleans. She worked as a postdoctoral fellow in Dr. Darwin Prockop's lab at Tulane Center for Gene Therapy until January 2004 and then became a research instructor in the same laboratory. Dr. Pochampally is currently an assistant professor in the Department of Pharmacology at Tulane University Health Sciences Center. The general focus of Dr. Pochampally's research is to understand the survival properties of serum deprivation resistant MSCs (SD-MSCS) and their therapeutic potential in various disease models. SD-MSCs are the most primitive subpopulation in the heterogeneous population of mesenchymal stem cells from bone marrow stroma. Her current projects include studying the role of (a) epigenetic regulation, micro-RNA regulation and post translational regulation in the survival of the SD-MSCs, and (b) the engraftment and differentiation potential of MSCs and SD-MSCs in acute mouse myocardial infarction and in chick embryo models. Dr. Pochampally is also interested in characterizing the cancer stem cells of osteosarcoma.

Recent Publications:

Pochampally R, Smith J, Prockop DJ. Serum deprivation of human marrow stromal cells (hMSCs) selects for a sub-population of early progenitor cells with enhanced expression of OCT-4 and other embryonic genes. Blood, 103(5): 1647-57, 2004.
Pochampally R, Li C, Lu W, Luftig R, Chen J. Temperature sensitive mutants of p53 homologs. Biochem Biophys Res Commun, 279(3): 1001-1010, 2000.
Lu W, Pochampally R, Chen L, Traidej M, Wang Y, Chen J. Nuclear exclusion of p53 in a subset of tumors requires MDM2 function. Oncogene, 19(2): 232-40, 2000.
Pochampally R, Fodera B, Chen L, Lu W, Chen J. Activation of an MDM2-specific caspase by p53 in the absence of apoptosis. J. Bio Chem, 274(21): 15271-15277, 1999.
Pochampally R, Fodera B, Chen L, Lu W, Chen J. A 60 kd MDM2 isoform is produced by caspase cleavage in nonapototic tumor cells. Oncogene, 17(20): 2629-36, 1998.

Eboni Price, M.D., M.P.H.
Assistant Professor of Medicine
Adjunct Assistant Professor of Epidemiology
Medical Director, Tulane University Community Health Center at Covenant House
TCC Contributing Member
eprice@tulane.edu
(504) 988-7809, (504) 988-3971 fax
1430 Tulane Ave., Box SL-12, New Orleans, LA 70112-2699

Biographical Narrative:
Dr. Price obtained her medical degree in 1999 from Johns Hopkins School of Medicine. In 2002, she completed her residency training in internal medicine at Baylor College of Medicine. From 2002 to 2005, she trained in a general internal medicine fellowship in medical education and research at Johns Hopkins and obtained a master of public health degree in 2004 from the Johns Hopkins Bloomberg School of Public Health. Her research interests include minority healthcare disparities with a focus on cancer prevention, and physician training in doctor-patient communication and cultural competency as strategies to improve health care quality.

Recent Publications:

Beach MC, Cooper LA, Robinson KA, Price EG, Gary TL, Jenckes MW, Gozu A, Smarth C, Palacio A, Feuerstein CJ, Bass EB, Powe NR. Strategies for improving minority healthcare quality. Evidence Report/Technology Assessment No. 90 (Prepared by the Johns Hopkins University Evidence-Based Practice Center, Baltimore, MD) AHRQ Publication No. 04-E008-02. Rockville, MD: Agency for Healthcare Research and Quality. January 2004.
Beach MC, Gary TL, Price EG, Robinson K, Gozu A, Palacio A, Smarth C, Jenckes M, Feuerstein C, Bass EB, Powe NR, Cooper LA. Improving health care quality for racial/ethnic minorities: a systematic review of the best evidence regarding provider and organization interventions. BMC Public Health, 6(1): 104, 2006.

Darwin J. Prockop, M.D., Ph.D.
Professor and Director, Center for Gene Therapy
TCC Program Member
dprocko@tulane.edu
(504) 988-7711, (504) 988-7710 fax
1430 Tulane Ave., SL-99, New Orleans, LA 70112

Biographical Narrative:
Dr. Prockop holds degrees from Haverford College (B.D.), Oxford University (Hon. B.A.), University of Pennsylvania (M.D.), and George Washington University (Ph.D.). He also holds honorary degrees from the University of South Florida, Oulu University of Finland, George Washington University, and the University of Manchester in the U.K. He is a member of the National Academy of Sciences (USA), the Academy of Finland and the Institute of Medicine (USA). His major research interests include adult stem progenitor cells from bone marrow (MSCs), the biology of MSCs, animal models for testing MSCs, and clinical trials with MSCs.

Recent Publications:

Ylostalo J, Smith JR, Pochampally RR, Matz R, Sekiya I, Larson BL, Vuoristo JR, Prockop DJ. Use of differentiating adult stem cells (MSCs) to identify new downstream target genes for transcription factors. Stem Cells, 24:642-52, 2006.
Spees JS, Olson SD, Whitney MJ, Prockop DJ. Mitochondrial transfer between cells can rescue aerobic respiration. Proceedings of the National Academy of Sciences, 103:1283-1288, 2006.
Munoz JR, Stoutenger BR, Robinson AP, Spees JL, Prockop DJ. Human stem/progenitor cells from bone marrow promote neurogenesis of endogenous neural stem cells in the hippocampus of mice. Proceedings of the National Academy of Sciences, 102: 18171-8176, 2005.
Gunn WG, Conley A, Deininger L, Olson SD, Prockop DJ, Gregory CA. A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and IL-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Stem Cells, November 17 (epub. Ahead of print), 2005.
Lee RH, Hsu SC, Munoz J, Jung JS, Lee NR, Pochampally R, Prockop DJ. A subset of human rapidly-self renewing marrow cells (MSCs) preferentially engraft in mice. Blood, 107: 2153-61, 2006.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Return to the top of this page.

Return to the Tulane Cancer Center homepage.

Calendars

Clinical Trials

Faculty

Links

Location

News

Site index

This page is http://www.som.tulane.edu/cancer/TCCnames/facp.html
This page was last updated on

Tulane Cancer Center, Box SL-68
1430 Tulane Avenue
New Orleans, Louisiana 70112-2699
(504) 988-6060, fax (504) 988-6077
http://www.som.tulane.edu/cancer